Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)

NCT00802737 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukaemia, Lymphocytic, Chronic

Interventions

DRUG: Ofatumumab

Sponsor

GlaxoSmithKline

Collaborators

[object Object]